Individual motile CD4+ T cells can participate in efficient multikilling through conjugation to multiple tumor cells

Cancer Immunology Research

Volumn 3, Issue 5, 2015, Pages 473-482

  Liadi, Ivan ^a   Singh, Harjeet ^b   Romain, Gabrielle ^a   Rey Villamizar, Nicolas ^a   Merouane, Amine ^a   Adolacion, Jay R T ^a   Kebriaei, Partow ^b   Huls, Helen ^b   Qiu, Peng ^c   Roysam, Badrinath ^a   Cooper, Laurence J N ^b   Varadarajan, Navin ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Emory University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GRANZYME; LYMPHOCYTE ANTIGEN RECEPTOR;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL KILLING; CELL KINETICS; CELL MEDIATED CYTOTOXICITY; CELL MOTILITY; CONJUGATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROSCOPY; TIME LAPSE IMAGING; TUMOR CELL; TUMOR IMMUNITY; CELL LINE; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; NEOPLASM; TUMOR CELL LINE;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL LINE, TUMOR; GRANZYMES; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84962320722     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0195     Document Type: Article

References (43)

1. Kalos M, June CH. Adoptive T-cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013;39:49-60.
2. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388-98.
3. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014;257:107-26.
4. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013;10: 267-76.
5. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra138.
6. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
7. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010;116:1035-44.
8. Spear P, Barber A, Sentman CL. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology 2013;2:e23564.
9. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012;23:1043-53.
10. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011;118:6050-6.
11. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3: 95ra73.
12. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9.
13. + T lymphocytes. Nature 2003;421:852-6.
14. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591-601.
15. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
16. + T cells against NY-ESO-1. N Engl J Med 2008;358:2698-703.
17. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637-50.
18. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010;207:651-67.
19. Roach KL, King KR, Uygun BE, Kohane IS, Yarmush ML, Toner M. Highthroughput single-cell bioinformatics. Biotechnol Prog 2009;25:1772-9.
20. Deutsch M, Deutsch A, Shirihai O, Hurevich I, Afrimzon E, Shafran Y, et al. A novel miniature cell retainer for correlative high-content analysis of individual untethered non-adherent cells. Lab Chip 2006;6:995-1000.
21. Liadi I, Roszik J, Romain G, Cooper LJ, Varadarajan N. Quantitative high throughput single-cell cytotoxicity assay for T cells. J Vis Exp, 2013;72: e50058.
22. Yamanaka YJ, Berger CT, Sips M, Cheney PC, Alter G, Love JC. Single-cell analysis of the dynamics and functional outcomes of interactions between human natural killer cells and target cells. Integr Biol 2012;4:1175-84.
23. Vanherberghen B, Olofsson PE, Forslund E, Sternberg-Simon M, Khorshidi MA, Pacouret S, et al. Classification of human natural killer cells based on migration behavior and cytotoxic response. Blood 2013;121:1326-34.
24. Romain G, Senyukov V, Rey-Villamizar N, Merouane A, Kelton W, Liadi I, et al. Antibody Fc-engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood 2014; 124:3241-9.
25. Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 2011;71: 3516-27.
26. Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS ONE 2013;8:e64138.
27. Izsvak Z, Ivics Z. Sleeping beauty transposition: biology and applications for molecular therapy. Mol Ther 2004;9:147-56.
28. Lex A, Streit M, Schutz HJ, Partl C, Schmalstieg D, Park PJ, et al. StratomeX: visual analysis of large-scale heterogeneous genomics data for cancer subtype characterization. Comput Graph Forum 2012;31:1175-84.
29. + T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function. PLoS ONE 2014;9: e87873.
30. Henkart PA, Millard PJ, Reynolds CW, Henkart MP. Cytolytic activity of purified cytoplasmic granules from cytotoxic rat large granular lymphocyte tumors. J Exp Med 1984;160:75-93.
31. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol 2007;7:532-42.
32. Romer PS, Berr S, Avota E, Na SY, Battaglia M, ten Berge I, et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 2011;118: 6772-82.
33. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709-20.
34. Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, et al. Human TH17 cells are long-lived effector memory cells. Sci Transl Med 2011;3:104ra100.
35. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114:1141-9.
36. Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specificT-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 2005;28:53-62.
37. Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15. Blood 2014;123:3750-9.
38. Kiaii S, Clear AJ, Ramsay AG, Davies D, Sangaralingam A, Lee A, et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol 2013;31:2654-61.
39. Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005;115:1797-805.
40. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, et al. Follicular lymphoma cells induce T-cell immunological synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009;114: 4713-20.
41. Zinselmeyer BH, Heydari S, Sacristan C, Nayak D, Cammer M, Herz J, et al. PD-1 promotes immune exhaustion by inducing antiviral T-cell motility paralysis. J Exp Med 2013;210:757-74.
42. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006;313:1972-5.
43. Pentcheva-Hoang T, Simpson TR, Montalvo-Ortiz W, Allison JP. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility. Cancer Immunol Res 2014;2: 970-80.